Last reviewed · How we verify
Bevazizumab intravitreal injection
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye. Used for Neovascular age-related macular degeneration (wet AMD), Diabetic macular edema, Retinal vein occlusion with macular edema.
At a glance
| Generic name | Bevazizumab intravitreal injection |
|---|---|
| Also known as | Avastin Injection |
| Sponsor | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab binds to and neutralizes VEGF, a key signaling molecule that promotes pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF, the drug reduces abnormal blood vessel growth and leakage, stabilizing or improving vision in conditions characterized by retinal neovascularization and macular edema. When administered as an intravitreal injection, it delivers the therapeutic agent directly to the posterior segment of the eye.
Approved indications
- Neovascular age-related macular degeneration (wet AMD)
- Diabetic macular edema
- Retinal vein occlusion with macular edema
- Proliferative diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain or discomfort
- Floaters
- Endophthalmitis
- Retinal detachment
- Cataract progression
Key clinical trials
- Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia (PHASE3)
- Intraocular Bevacizumab (Avastin) for Rubeosis Iridis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: